Csf1r (colony stimulating factor 1 receptor) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Csf1r (colony stimulating factor 1 receptor) Rattus norvegicus
Symbol: Csf1r
Name: colony stimulating factor 1 receptor
RGD ID: 2425
Description: Enables organic cyclic compound binding activity and protein phosphatase binding activity. Involved in several processes, including negative regulation of cell differentiation; nervous system development; and positive regulation of cell population proliferation. Located in perikaryon. Used to study anti-basement membrane glomerulonephritis; bone development disease; crescentic glomerulonephritis; infertility; and lymphopenia. Human ortholog(s) of this gene implicated in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia; diabetes mellitus; gastrointestinal system cancer (multiple); lung cancer (multiple); and renal cell carcinoma. Orthologous to human CSF1R (colony stimulating factor 1 receptor); PARTICIPATES IN cytokine mediated signaling pathway; endocytosis pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 17beta-estradiol; 17beta-estradiol 3-benzoate.
Type: protein-coding
Previously known as: c-fms; CSF-1 receptor; CSF-1-R; CSF-1R; fms proto-oncogene; M-CSF-R; macrophage colony-stimulating factor 1 receptor; MGC125014; mrfms; proto-oncogene c-Fms; proto-oncogene fms
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Csf1rtm(EGFP)Tset  
Genetic Models: SD-Csf1rtm(EGFP)+/-/Tset SD-Csf1rtm(EGFP)-/-/Tset DA-Csf1rtm(EGFP)+/-/Hume DA-Csf1rtm(EGFP)-/-/Hume
Candidate Gene For: Eau7
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81856,834,152 - 56,860,804 (+)NCBIGRCr8
mRatBN7.21854,546,673 - 54,590,418 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1854,546,659 - 54,590,415 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1856,651,929 - 56,678,637 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01857,366,526 - 57,393,238 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01855,187,862 - 55,214,296 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01856,414,493 - 56,458,300 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1856,414,488 - 56,458,300 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01855,662,670 - 55,689,297 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41857,080,324 - 57,107,295 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1852,716,221 - 52,742,736 (+)NCBICelera
Cytogenetic Map18q12.1NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (ISO)
acute myeloid leukemia  (ISO)
adult-onset leukoencephalopathy with axonal spheroids and pigmented glia  (ISO)
Alzheimer's disease  (ISO)
anti-basement membrane glomerulonephritis  (IDA,IMP)
bone development disease  (IMP)
Brain Hypoxia-Ischemia  (IEP,IMP)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
Carcinoma, Lewis Lung  (ISO)
Carotid Artery Injuries  (IEP)
cervical squamous cell carcinoma  (ISO)
cervix uteri carcinoma in situ  (ISO)
colon adenocarcinoma  (ISO)
colorectal cancer  (ISO)
colorectal carcinoma  (ISO)
crescentic glomerulonephritis  (IMP)
diabetes mellitus  (ISO)
Diabetic Nephropathies  (IEP,ISO)
disease of cellular proliferation  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Arthritis  (IMP)
Experimental Colitis  (ISO)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (ISO)
familial adenomatous polyposis  (ISO)
familial adenomatous polyposis 1  (ISO)
Foreign-Body Reaction  (IMP)
frontotemporal dementia  (ISO)
gastrointestinal stromal tumor  (ISO)
genetic disease  (ISO)
Hematologic Neoplasms  (ISO)
hepatocellular carcinoma  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
infertility  (IMP)
Kidney Reperfusion Injury  (ISO)
Leukoencephalopathies  (ISO)
liver cirrhosis  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
lung non-small cell carcinoma  (ISO)
lung small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphopenia  (IMP)
malignant pleural mesothelioma  (ISO)
myeloid neoplasm  (ISO)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
Neurodevelopmental Disorders  (ISO)
Optic Nerve Injuries  (IEP)
Parkinsonism  (ISO)
prostate carcinoma in situ  (ISO)
Prostatic Neoplasms  (ISO)
renal cell carcinoma  (ISO)
stomach cancer  (ISO)
Transplant Rejection  (IMP)
ureteral obstruction  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(1->4)-beta-D-glucan  (ISO)
1,2-dimethylhydrazine  (ISO)
1,4-benzoquinone  (ISO)
1-naphthyl isothiocyanate  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-tert-butylhydroquinone  (ISO)
3,4-methylenedioxymethamphetamine  (ISO)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-nonylphenol  (ISO)
4-tert-Octylphenol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP)
acetamide  (EXP)
acrylamide  (EXP)
aflatoxin B1  (EXP)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
antirheumatic drug  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
benzene  (ISO)
benzene-1,2,4-triol  (ISO)
benzo[a]pyrene  (EXP,ISO)
beta-naphthoflavone  (ISO)
bexarotene  (EXP)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bucladesine  (ISO)
buspirone  (EXP)
butanal  (ISO)
C60 fullerene  (EXP)
cadmium atom  (ISO)
cadmium dichloride  (EXP)
calcitriol  (ISO)
carbon nanotube  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
crocidolite asbestos  (ISO)
Cuprizon  (EXP)
curcumin  (ISO)
cyclosporin A  (ISO)
D-gluconic acid  (EXP)
deguelin  (ISO)
deoxycholic acid  (EXP)
dexamethasone  (ISO)
dichlorine  (EXP)
diclofenac  (ISO)
diethylstilbestrol  (ISO)
dimethyl fumarate  (ISO)
dimethyl sulfoxide  (ISO)
doxorubicin  (ISO)
Echimidine  (EXP)
epoxiconazole  (ISO)
ethanol  (ISO)
fenofibrate  (EXP)
fluoxetine  (EXP)
flutamide  (EXP)
folpet  (ISO)
fulvestrant  (ISO)
gamma-tocopherol  (ISO)
genistein  (EXP)
gentamycin  (EXP)
GW 4064  (ISO)
Heliotrine  (EXP)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxytyrosol  (ISO)
indoles  (EXP)
isotretinoin  (ISO)
KN-93  (ISO)
Lasiocarpine  (EXP)
lead diacetate  (ISO)
lipopolysaccharide  (ISO)
maneb  (ISO)
methamphetamine  (EXP)
methotrexate  (ISO)
N-(6-acetamidohexyl)acetamide  (ISO)
N-acetyl-L-cysteine  (ISO)
N-nitrosodimethylamine  (EXP)
naringin  (ISO)
nefazodone  (EXP)
nickel atom  (ISO)
nimesulide  (EXP)
nitric oxide  (ISO)
Octicizer  (ISO)
oleuropein  (ISO)
ozone  (EXP,ISO)
p-tert-Amylphenol  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
pentanal  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
pexidartinib  (ISO)
phenobarbital  (ISO)
pirinixic acid  (EXP,ISO)
pluronic P-123  (ISO)
Poloxamer  (ISO)
ponatinib  (ISO)
pravastatin  (EXP,ISO)
propanal  (ISO)
propiconazole  (EXP)
raloxifene  (EXP)
resveratrol  (EXP,ISO)
SB 203580  (ISO)
senecionine  (EXP)
Senkirkine  (EXP)
silicon dioxide  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (ISO)
Soman  (EXP)
starch  (EXP)
streptozocin  (EXP)
sulfadimethoxine  (EXP)
sunitinib  (ISO)
tamoxifen  (EXP)
temozolomide  (ISO)
testosterone  (EXP,ISO)
tetrachloromethane  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
tocopherol  (ISO)
tributyl phosphate  (ISO)
triphenyl phosphate  (EXP,ISO)
triptonide  (ISO)
tris(2-butoxyethyl) phosphate  (ISO)
tris(2-chloroethyl) phosphate  (ISO)
troglitazone  (ISO)
valproic acid  (ISO)
vinclozolin  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
animal organ development  (IEA)
axon guidance  (IEA,ISO)
cardiac muscle cell proliferation  (IEP)
cell population proliferation  (ISO)
cell surface receptor protein tyrosine kinase signaling pathway  (IEA,ISO,ISS)
cell-cell junction maintenance  (IEA,ISO)
cellular response to cytokine stimulus  (ISO,ISS)
cellular response to macrophage colony-stimulating factor stimulus  (IEP,ISO,ISS)
cellular response to transforming growth factor beta stimulus  (IEP)
cellular response to tumor necrosis factor  (IEP)
cytokine-mediated signaling pathway  (IEA,ISO)
dentate gyrus development  (IMP)
forebrain neuron differentiation  (IEA,ISO)
hemopoiesis  (ISO)
innate immune response  (IEA)
macrophage colony-stimulating factor signaling pathway  (IEA,ISO)
microglia development  (IMP)
microglial cell activation  (IMP)
microglial cell proliferation  (IDA,IEA,ISO)
monocyte homeostasis  (IMP)
mononuclear cell differentiation  (IEP)
myoblast proliferation  (IEP)
negative regulation of apoptotic process  (IEA,ISO)
negative regulation of cell population proliferation  (IEA,ISO)
negative regulation of cellular process  (IMP)
negative regulation of epithelial cell differentiation  (IMP)
negative regulation of myotube differentiation  (IMP)
negative regulation of platelet formation  (IMP)
neuron projection extension  (IMP)
neutrophil homeostasis  (IMP)
olfactory bulb development  (IEA,ISO)
osteoclast differentiation  (HEP,IBA,IEA,ISO,ISS)
positive regulation by host of viral process  (IEA,ISO)
positive regulation of astrocyte activation  (IMP)
positive regulation of bone mineralization  (IMP)
positive regulation of cell cycle G1/S phase transition  (IMP)
positive regulation of cell migration  (IBA)
positive regulation of cell motility  (ISO)
positive regulation of cell population proliferation  (ISO,ISS)
positive regulation of chemokine production  (IEA,ISO)
positive regulation of ERK1 and ERK2 cascade  (IEA,ISO,ISS)
positive regulation of gene expression  (IMP)
positive regulation of leukocyte proliferation  (IMP)
positive regulation of lymphocyte proliferation  (IMP)
positive regulation of macrophage chemotaxis  (IEA,ISO)
positive regulation of macrophage migration  (IMP)
positive regulation of macrophage proliferation  (IEA,IMP,ISO)
positive regulation of myoblast proliferation  (IMP)
positive regulation of osteoclast differentiation  (IMP)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction  (IEA,ISO,ISS)
positive regulation of protein phosphorylation  (ISO)
positive regulation of tumor necrosis factor production  (IMP)
positive regulation of tyrosine phosphorylation of STAT protein  (IEA,ISO,ISS)
regulation of actin cytoskeleton organization  (IEA,ISO,ISS)
regulation of bone resorption  (IMP)
regulation of cell shape  (IEA,ISO,ISS)
regulation of macrophage migration  (ISO,ISS)
regulation of MAPK cascade  (IBA)
regulation of mononuclear cell proliferation  (IMP)
response to axon injury  (IEP)
response to hypoxia  (IEP)
response to ischemia  (IEA,ISO)
response to lipopolysaccharide  (IEP)
response to mechanical stimulus  (IEP)
response to organic cyclic compound  (IEP)
response to organonitrogen compound  (IEP)
ruffle organization  (IEA,ISO,ISS)
skeletal muscle cell proliferation  (IEP)
skeletal muscle tissue development  (IEP)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Baghdadi M, etal., Sci Rep. 2018 Jan 11;8(1):418. doi: 10.1038/s41598-017-18796-8.
2. Colony-stimulating factor 1 (CSF-1) is involved in an autocrine growth control of rat myogenic cells. Borycki AG, etal., Exp Cell Res. 1995 May;218(1):213-22. doi: 10.1006/excr.1995.1149.
3. Molecular cloning of CSF-1 receptor from rat myoblasts. Sequence analysis and regulation during myogenesis. Borycki AG, etal., Growth Factors 1992;6(3):209-18.
4. Molecular cloning of CSF-1 receptor from rat myoblasts. Sequence analysis and regulation during myogenesis. Borycki AG, etal., Growth Factors 1992;6(3):209-18.
5. Repression of the CSF-1 receptor (c-fms proto-oncogene product) by antisense transfection induces G1-growth arrest in L6 alpha 1 rat myoblasts. Borycki AG, etal., Oncogene. 1995 May 4;10(9):1799-811.
6. Proto-oncogene expression in proliferating and differentiating cardiac and skeletal muscle. Claycomb WC and Lanson NA, Biochem J. 1987 Nov 1;247(3):701-6. doi: 10.1042/bj2470701.
7. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. Conway JG, etal., J Pharmacol Exp Ther. 2008 Jul;326(1):41-50. doi: 10.1124/jpet.107.129429. Epub 2008 Apr 23.
8. CSF1R methylation is a key regulatory mechanism of tumor-associated macrophages in hepatocellular carcinoma. Cui B, etal., Oncol Lett. 2020 Aug;20(2):1835-1845. doi: 10.3892/ol.2020.11726. Epub 2020 Jun 11.
9. [Methylation status of c-fms oncogene in hepatocellular carcinoma and its relation with clinical pathology]. Cui J and Yang D, Zhonghua Gan Zang Bing Za Zhi. 2001 Jun;9(3):137-8.
10. The potential mechanism of INHBC and CSF1R in diabetic nephropathy. Du XY, etal., Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1970-1978. doi: 10.26355/eurrev_202002_20374.
11. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. Fassunke J, etal., BMC Mol Biol. 2010 Dec 20;11:100. doi: 10.1186/1471-2199-11-100.
12. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
13. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
14. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Hammes LS, etal., Gynecol Oncol. 2008 Jun 18.
15. Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Han Y, etal., Am J Physiol Renal Physiol. 2013 Apr 15;304(8):F1043-53. doi: 10.1152/ajprenal.00389.2012. Epub 2013 Feb 13.
16. c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat. Han Y, etal., Lab Invest. 2011 Jul;91(7):978-91. doi: 10.1038/labinvest.2011.61. Epub 2011 Apr 25.
17. Response of amoeboid microglia/brain macrophages in fetal rat brain exposed to a teratogen. Hao AJ, etal., J Neurosci Res. 2001 Apr 1;64(1):79-93. doi: 10.1002/jnr.1056.
18. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Hasinoff BB, Toxicol Appl Pharmacol. 2010 Apr 15;244(2):190-5. doi: 10.1016/j.taap.2009.12.032. Epub 2010 Jan 4.
19. A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system. Horvat A, etal., J Neurosci 2001 Feb 1;21(3):865-74.
20. Macrophage colony-stimulating factor induces prolactin expression in rat pituitary gland. Hoshino S, etal., Zoolog Sci. 2014 Jun;31(6):390-7. doi: 10.2108/zs130226.
21. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Hoves S, etal., J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.
22. Rh-CSF1 attenuates neuroinflammation via the CSF1R/PLCG2/PKCε pathway in a rat model of neonatal HIE. Hu X, etal., J Neuroinflammation. 2020 Jun 10;17(1):182. doi: 10.1186/s12974-020-01862-w.
23. Rh-CSF1 Attenuates Oxidative Stress and Neuronal Apoptosis via the CSF1R/PLCG2/PKA/UCP2 Signaling Pathway in a Rat Model of Neonatal HIE. Hu X, etal., Oxid Med Cell Longev. 2020 Oct 7;2020:6801587. doi: 10.1155/2020/6801587. eCollection 2020.
24. CSF-1 receptor-dependent colon development, homeostasis and inflammatory stress response. Huynh D, etal., PLoS One. 2013;8(2):e56951. doi: 10.1371/journal.pone.0056951. Epub 2013 Feb 22.
25. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Ide H, etal., Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14404-9. Epub 2002 Oct 15.
26. A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony-stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. Iio E, etal., Int J Cancer. 2016 Mar 15;138(6):1462-71. doi: 10.1002/ijc.29880. Epub 2015 Oct 20.
27. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Iyoda M, etal., Kidney Int. 2009 May;75(10):1060-70. doi: 10.1038/ki.2009.43. Epub 2009 Feb 25.
28. Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation. Jang MH, etal., J Immunol. 2006 Sep 15;177(6):4055-63.
29. Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting. Jiang Q, etal., Front Bioeng Biotechnol. 2020 Jul 14;8:783. doi: 10.3389/fbioe.2020.00783. eCollection 2020.
30. Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers. Kakiuchi-Kiyota S, etal., Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):188-99. doi: 10.1097/PAI.0b013e31828e7104.
31. A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females. Kang HG, etal., J Thorac Oncol. 2014 Nov;9(11):1647-55. doi: 10.1097/JTO.0000000000000310.
32. Expression of CSF-1 receptor on TRAP-positive multinuclear cells around the erupting molars in rats. Kawakami M, etal., J Craniofac Genet Dev Biol. 1999 Oct-Dec;19(4):213-20.
33. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Kluger HM, etal., Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):173-7.
34. Differential expression of protooncogenes related to transformation and cancer progression in rat myoblasts. Leibovitch SA, etal., Cancer Res. 1986 Aug;46(8):4097-103.
35. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Lim AK, etal., Diabetologia. 2009 May 23.
36. Multiple receptor tyrosine kinases are expressed in adult rat retinal ganglion cells as revealed by single-cell degenerate primer polymerase chain reaction. Lindqvist N, etal., Ups J Med Sci. 2010 Feb;115(1):65-80. doi: 10.3109/03009731003597119.
37. Expression of macrophage colony-stimulating factor (M-CSF) and its receptor in streptozotocin-induced diabetic rats. Liu W, etal., Curr Eye Res. 2009 Feb;34(2):123-33. doi: 10.1080/02713680802650369.
38. Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations. Lohela M, etal., Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5086-95. doi: 10.1073/pnas.1419899111. Epub 2014 Nov 10.
39. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Ma FY, etal., Am J Physiol Renal Physiol. 2009 Jan;296(1):F177-85. Epub 2008 Nov 5.
40. Macrophages contribute to cellular but not humoral mechanisms of acute rejection in rat renal allografts. Ma FY, etal., Transplantation. 2013 Dec 15;96(11):949-57. doi: 10.1097/TP.0b013e3182a4befa.
41. Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-α in combination with TGF-β in rats. Matsubara R, etal., PLoS One. 2012;7(10):e47930. doi: 10.1371/journal.pone.0047930. Epub 2012 Oct 24.
42. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Menke J, etal., Cancer Res. 2012 Jan 1;72(1):187-200. doi: 10.1158/0008-5472.CAN-11-1232. Epub 2011 Nov 3.
43. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
44. Role of macrophage colony-stimulating factor in the development of neointimal thickening following arterial injury. Mishra V, etal., Cardiovasc Pathol. 2016 Jul-Aug;25(4):284-292. doi: 10.1016/j.carpath.2016.04.003. Epub 2016 Apr 11.
45. In vitro proliferation of axotomized rat facial nucleus-derived activated microglia in an autocrine fashion. Nakajima K, etal., J Neurosci Res. 2006 Aug 1;84(2):348-59. doi: 10.1002/jnr.20882.
46. Expressions of RANKL/RANK and M-CSF/c-fms in root resorption lacunae in rat molar by heavy orthodontic force. Nakano Y, etal., Eur J Orthod. 2011 Aug;33(4):335-43. doi: 10.1093/ejo/cjq068. Epub 2010 Sep 10.
47. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
48. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Ohno H, etal., Mol Cancer Ther. 2006 Nov;5(11):2634-43.
49. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer. Okugawa Y, etal., Int J Oncol. 2018 Aug;53(2):737-749. doi: 10.3892/ijo.2018.4406. Epub 2018 May 16.
50. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
51. Online Mendelian Inheritance in Man, OMIM (TM). Online Mendelian Inheritance in Man, OMIM (TM).
52. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Pass HI, etal., Oncotarget. 2016 Aug 30;7(35):56408-56421. doi: 10.18632/oncotarget.10895.
53. Analysis of homozygous and heterozygous Csf1r knockout in the rat as a model for understanding microglial function in brain development and the impacts of human CSF1R mutations. Patkar OL, etal., Neurobiol Dis. 2021 Apr;151:105268. doi: 10.1016/j.nbd.2021.105268. Epub 2021 Jan 12.
54. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
55. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Priceman SJ, etal., Blood. 2010 Feb 18;115(7):1461-71. doi: 10.1182/blood-2009-08-237412. Epub 2009 Dec 11.
56. Pleiotropic Impacts of Macrophage and Microglial Deficiency on Development in Rats with Targeted Mutation of the Csf1r Locus. Pridans C, etal., J Immunol. 2018 Nov 1;201(9):2683-2699. doi: 10.4049/jimmunol.1701783. Epub 2018 Sep 24.
57. Characterization of differential gene expression profiles in diabetic embryopathy using DNA microarray analysis. Reece EA, etal., Am J Obstet Gynecol. 2006 Oct;195(4):1075-80. doi: 10.1016/j.ajog.2006.05.054.
58. GOA pipeline RGD automated data pipeline
59. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
60. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
61. Comprehensive gene review and curation RGD comprehensive gene curation
62. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Richardsen E, etal., Histopathology. 2008 May 28;.
63. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Ries CH, etal., Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.
64. Paradoxical stimulation of normal and leukemic rat hematopoiesis by monoclonal antibody to CSF-1 receptor. Shadduck RK, etal., Exp Hematol. 1996 Feb;24(2):314-7.
65. Inflammatory Foreign Body Response Induced by Neuro-Implants in Rat Cortices Depleted of Resident Microglia by a CSF1R Inhibitor and Its Implications. Sharon A, etal., Front Neurosci. 2021 Mar 26;15:646914. doi: 10.3389/fnins.2021.646914. eCollection 2021.
66. Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer. Shi X, etal., Cell Mol Gastroenterol Hepatol. 2020;10(2):391-418. doi: 10.1016/j.jcmgh.2020.04.002. Epub 2020 Apr 15.
67. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. Slattery ML, etal., Genes Chromosomes Cancer. 2017 Nov;56(11):769-787. doi: 10.1002/gcc.22481. Epub 2017 Jul 30.
68. c-fms is present in primary tumours as well as in their metastases in bone marrow. Storga D, etal., Int J Exp Pathol. 1992 Aug;73(4):527-33.
69. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Swierczak A, etal., Cancer Immunol Res. 2014 Aug;2(8):765-76. doi: 10.1158/2326-6066.CIR-13-0190. Epub 2014 Apr 29.
70. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. Szymanowska-Narloch A, etal., Adv Med Sci. 2013;58(2):196-206. doi: 10.2478/ams-2013-0025.
71. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Toma MI, etal., Neoplasia. 2008 Jul;10(7):634-42.
72. Macrophage colony-stimulating factor release and receptor expression in bone cells. Weir EC, etal., J Bone Miner Res. 1993 Dec;8(12):1507-18. doi: 10.1002/jbmr.5650081214.
73. Localization and expression of CSF-1 receptor in rat dental follicle cells. Wise GE, etal., J Dent Res. 1997 Jun;76(6):1244-9. doi: 10.1177/00220345970760060301.
74. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Yang DH, etal., Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):86-9.
75. Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. Yang M, etal., Blood. 2006 Mar 15;107(6):2262-70. doi: 10.1182/blood-2005-08-3365. Epub 2005 Nov 22.
76. Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients. Yang S, etal., Int J Oncol. 2012 May;40(5):1590-600. doi: 10.3892/ijo.2012.1341. Epub 2012 Jan 20.
77. Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. Yoo SS, etal., Cancer Genet. 2017 Apr;212-213:8-12. doi: 10.1016/j.cancergen.2017.03.003. Epub 2017 Mar 20.
78. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Zhang L, etal., Cell. 2020 Apr 16;181(2):442-459.e29. doi: 10.1016/j.cell.2020.03.048.
79. CSF-1 signaling mediates recovery from acute kidney injury. Zhang MZ, etal., J Clin Invest. 2012 Dec 3;122(12):4519-32. doi: 10.1172/JCI60363. Epub 2012 Nov 12.
80. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients. Zhang T, etal., Aging (Albany NY). 2021 Jan 10;13(3):3819-3842. doi: 10.18632/aging.202351. Epub 2021 Jan 10.
Additional References at PubMed
PMID:2408759   PMID:7681396   PMID:7683918   PMID:8007983   PMID:8262059   PMID:8922060   PMID:12477932   PMID:15117969   PMID:15860730   PMID:16170366   PMID:16705167   PMID:18814279  
PMID:19017797   PMID:19100238   PMID:20504948   PMID:20536329   PMID:20829061   PMID:20889566   PMID:21610095   PMID:22451653   PMID:22542597   PMID:23392676   PMID:26754294   PMID:34081701  
PMID:37059596   PMID:37167456  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81856,834,152 - 56,860,804 (+)NCBIGRCr8
mRatBN7.21854,546,673 - 54,590,418 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1854,546,659 - 54,590,415 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1856,651,929 - 56,678,637 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01857,366,526 - 57,393,238 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01855,187,862 - 55,214,296 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01856,414,493 - 56,458,300 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1856,414,488 - 56,458,300 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01855,662,670 - 55,689,297 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41857,080,324 - 57,107,295 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1852,716,221 - 52,742,736 (+)NCBICelera
Cytogenetic Map18q12.1NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh385150,053,295 - 150,113,365 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl5150,053,291 - 150,113,372 (-)EnsemblGRCh38hg38GRCh38
GRCh375149,432,858 - 149,492,928 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 365149,413,051 - 149,473,128 (-)NCBINCBI36Build 36hg18NCBI36
Build 345149,413,050 - 149,473,128NCBI
Celera5145,514,237 - 145,574,309 (-)NCBICelera
Cytogenetic Map5q32NCBI
HuRef5144,580,804 - 144,640,914 (-)NCBIHuRef
CHM1_15148,865,545 - 148,925,516 (-)NCBICHM1_1
T2T-CHM13v2.05150,589,842 - 150,649,957 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391861,238,644 - 61,264,211 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1861,233,670 - 61,265,221 (+)EnsemblGRCm39 Ensembl
GRCm381861,105,572 - 61,131,139 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1861,100,598 - 61,132,149 (+)EnsemblGRCm38mm10GRCm38
MGSCv371861,265,226 - 61,290,793 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361861,230,941 - 61,256,506 (+)NCBIMGSCv36mm8
Celera1862,392,678 - 62,417,929 (+)NCBICelera
Cytogenetic Map18E1NCBI
cM Map1834.41NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554154,434,453 - 4,461,751 (+)EnsemblChiLan1.0
ChiLan1.0NW_0049554154,434,486 - 4,462,505 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1-v24145,283,044 - 145,316,620 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan15143,422,593 - 143,481,722 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v05145,478,725 - 145,537,858 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.15151,483,948 - 151,543,128 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl5151,483,572 - 151,517,415 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1458,980,699 - 59,010,683 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl458,980,788 - 59,010,510 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha458,746,695 - 58,776,657 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0459,461,238 - 59,491,183 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl459,444,535 - 59,544,925 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1459,249,977 - 59,279,943 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0459,364,574 - 59,394,530 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0459,895,615 - 59,925,571 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024407213143,324,957 - 143,353,222 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365044,898,945 - 4,928,923 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365044,898,947 - 4,927,195 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl2151,102,147 - 151,147,633 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.12151,102,138 - 151,130,311 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.22157,855,536 - 157,882,913 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.12352,663,290 - 52,723,652 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2352,664,076 - 52,697,304 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603424,993,437 - 25,053,747 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046247749,363,908 - 9,391,986 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247749,363,156 - 9,391,939 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Csf1r
263 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:95
Count of miRNA genes:75
Interacting mature miRNAs:89
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1331733Bp233Blood pressure QTL 2333.97196arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182479697779788953Rat
1358358Sradr6Stress Responsive Adrenal Weight QTL 62.49adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)181194429959330563Rat
1331730Scl27Serum cholesterol level QTL 273.826blood HDL cholesterol amount (VT:0000184)serum high density lipoprotein cholesterol level (CMO:0000361)185229287559796643Rat
1331741Bp232Blood pressure QTL 2323.59112arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)182137289383213037Rat
1331742Bp228Blood pressure QTL 2283.88752arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331736Bp227Blood pressure QTL 2272.791arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)184671876359796643Rat
1300125Rf26Renal function QTL 263.2urine potassium amount (VT:0010539)urine potassium excretion rate (CMO:0000761)185253986365844950Rat
6893683Bw110Body weight QTL 1102.70.002body mass (VT:0001259)body weight (CMO:0000012)184334502283828827Rat
1331727Bp237Blood pressure QTL 2373.053arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940861698465Rat
9589041Epfw12Epididymal fat weight QTL 1217.080.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)184664067583828827Rat
8694432Bw165Body weight QTL 1653.810.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)184664067583828827Rat
1331774Bp226Blood pressure QTL 2264.41065arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
9589816Gluco68Glucose level QTL 687.250.001blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)182979296574792965Rat
61360EaeyExperimental allergic encephalomyelitis QTL y3nervous system integrity trait (VT:0010566)experimental autoimmune encephalomyelitis duration (CMO:0001424)184698893960377753Rat
2300177Bmd65Bone mineral density QTL 6519.70.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
2303120Mamtr8Mammary tumor resistance QTL 80.001mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)183135940883218561Rat
1578667Bss21Bone structure and strength QTL 213.5femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)181179151883218561Rat
12880368Bw187Body weight QTL 1870.045body mass (VT:0001259)body weight (CMO:0000012)185253976376104388Rat
61367Iddm4Insulin dependent diabetes mellitus QTL 42.330.0074blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)183819245583192455Rat
2293658Bmd23Bone mineral density QTL 237.30.0001femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)185146473363636873Rat
1359020Ppulsi2Prepulse inhibition QTL 22.71prepulse inhibition trait (VT:0003088)acoustic startle response measurement (CMO:0001519)185229287573997283Rat
2299160Iddm35Insulin dependent diabetes mellitus QTL 352.79blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)18420794160377792Rat
1331752Bw27Body weight QTL 272.963body mass (VT:0001259)body weight (CMO:0000012)185229287565845095Rat
9590318Scort22Serum corticosterone level QTL 227.640.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)182979296574792965Rat
1578661Bss20Bone structure and strength QTL 203.7femur morphology trait (VT:0000559)femoral neck cross-sectional area (CMO:0001697)181179151883218561Rat
1331754Bp230Blood pressure QTL 2304.61609arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182979296574792965Rat
12904069Cm123Cardiac mass QTL 1230.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)185253976376104388Rat
1331798Bp224Blood pressure QTL 2243.53873arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
12904070Cm124Cardiac mass QTL 1240.01heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)185253976376104388Rat
2303584Gluco55Glucose level QTL 552blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)184852004483828827Rat
12904071Am18Aortic mass QTL 180.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)185253976376104388Rat
61383Bp47Blood pressure QTL 4717.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)183127168160377755Rat
12904067Cm122Cardiac mass QTL 1220.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)185253976376104388Rat
1331806Bp229Blood pressure QTL 2294.36484arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876357867167Rat
2301417Bp319Blood pressure QTL 3190.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)185253976376104388Rat
12904073Kidm71Kidney mass QTL 710.001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)185253976376104388Rat
1331780Bp238Blood pressure QTL 2383.269arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876359796643Rat
738008Hcar14Hepatocarcinoma resistance QTL 144.3liver integrity trait (VT:0010547)liver nonremodeling tumorous lesion number (CMO:0001462)185146473383218561Rat
1331776Bp225Blood pressure QTL 2252.829arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)183135940859796643Rat
6903359Bp355Blood pressure QTL 3553.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)181194454459796478Rat
631518Bw11Body weight QTL 112.8body mass (VT:0001259)body weight (CMO:0000012)183587072380870723Rat
6903345Bp349Blood pressure QTL 3493.9arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
2313082Bss85Bone structure and strength QTL 850.80.0001long bone metaphysis morphology trait (VT:0000133)tibia midshaft total cross-sectional area (CMO:0001715)181495133759951337Rat
6903347Bp350Blood pressure QTL 3504.4arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135953059796478Rat
8694366Abfw8Abdominal fat weight QTL 86.380.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)184664067583828827Rat
631509Sald2Serum aldosterone level QTL 22.9blood aldosterone amount (VT:0005346)serum aldosterone level (CMO:0000487)185253976369140759Rat
6903349Bp351Blood pressure QTL 3513.5arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
738005Anxrr11Anxiety related response QTL 113.4exploratory behavior trait (VT:0010471)number of entries into a discrete space in an experimental apparatus (CMO:0000960)183003981375039813Rat
2300157Bmd66Bone mineral density QTL 6613.10.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
6903351Bp352Blood pressure QTL 3523.3arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
631274Sprol1Serum protein level QTL 15.3blood total protein amount (VT:0005567)serum total protein level (CMO:0000661)183139332077209694Rat
1358193Emca2Estrogen-induced mammary cancer QTL 21.6mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)181800759963571040Rat
2293704Bss35Bone structure and strength QTL 354.590.0002femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)182896485373964853Rat
2325839Bp348Blood pressure QTL 3480.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182557098570570985Rat
1600373Mamtr6Mammary tumor resistance QTL 6mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)181927890183218561Rat
2293708Bss46Bone structure and strength QTL 468.80.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)181179151863636873Rat
8694378Bw157Body weight QTL 1573.590.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)182979296574792965Rat
1600375Mcs22Mammary carcinoma susceptibility QTL 223.3mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)185253976363933058Rat
2303571Bw92Body weight QTL 923body mass (VT:0001259)body weight (CMO:0000012)184852004483828827Rat
1598826Anxrr20Anxiety related response QTL 203.04body movement coordination trait (VT:0005424)number of rearing movements in an experimental apparatus (CMO:0001752)184143297183828827Rat
61429Cia17Collagen induced arthritis QTL 174.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)183135940870263868Rat
7411719Strs5Sensitivity to stroke QTL 59.4cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)184999995865845095Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,563,748 - 54,563,853 (+)MAPPERmRatBN7.2
Rnor_6.01856,431,650 - 56,431,754NCBIRnor6.0
Rnor_5.01855,662,659 - 55,662,763UniSTSRnor5.0
RGSC_v3.41857,080,083 - 57,080,187UniSTSRGSC3.4
Celera1852,715,980 - 52,716,084UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,576,659 - 54,576,946 (+)MAPPERmRatBN7.2
Rnor_6.01856,444,563 - 56,444,849NCBIRnor6.0
Rnor_5.01855,675,572 - 55,675,858UniSTSRnor5.0
RGSC_v3.41857,093,038 - 57,093,324UniSTSRGSC3.4
Celera1852,728,892 - 52,729,178UniSTS
RH 3.4 Map18520.3UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,590,178 - 54,590,377 (+)MAPPERmRatBN7.2
Rnor_6.01856,458,064 - 56,458,262NCBIRnor6.0
Rnor_5.01855,689,061 - 55,689,259UniSTSRnor5.0
RGSC_v3.41857,107,059 - 57,107,257UniSTSRGSC3.4
Celera1852,742,500 - 52,742,698UniSTS
RH 3.4 Map18532.3UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,572,402 - 54,572,639 (+)MAPPERmRatBN7.2
Rnor_6.01856,440,306 - 56,440,542NCBIRnor6.0
Rnor_5.01855,671,315 - 55,671,551UniSTSRnor5.0
RGSC_v3.41857,088,781 - 57,089,017UniSTSRGSC3.4
Celera1852,724,635 - 52,724,871UniSTS
RH 3.4 Map18532.2UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,589,055 - 54,589,477 (+)MAPPERmRatBN7.2
Rnor_6.01856,456,941 - 56,457,362NCBIRnor6.0
Rnor_5.01855,687,938 - 55,688,359UniSTSRnor5.0
RGSC_v3.41857,105,936 - 57,106,357UniSTSRGSC3.4
Celera1852,741,377 - 52,741,798UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,567,833 - 54,568,481 (+)MAPPERmRatBN7.2
Rnor_6.01856,435,737 - 56,436,384NCBIRnor6.0
Rnor_5.01855,666,746 - 55,667,393UniSTSRnor5.0
RGSC_v3.41857,084,212 - 57,084,859UniSTSRGSC3.4
Celera1852,720,066 - 52,720,713UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,566,892 - 54,566,975 (+)MAPPERmRatBN7.2
Rnor_6.01856,434,796 - 56,434,878NCBIRnor6.0
Rnor_5.01855,665,805 - 55,665,887UniSTSRnor5.0
RGSC_v3.41857,083,271 - 57,083,353UniSTSRGSC3.4
Celera1852,719,125 - 52,719,207UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21854,589,765 - 54,590,407 (+)MAPPERmRatBN7.2
Rnor_6.01856,457,651 - 56,458,292NCBIRnor6.0
Rnor_5.01855,688,648 - 55,689,289UniSTSRnor5.0
RGSC_v3.41857,106,646 - 57,107,287UniSTSRGSC3.4
Celera1852,742,087 - 52,742,728UniSTS
Cytogenetic Map18q12.1UniSTS

Genetic Models
This gene Csf1r is modified in the following models/strains:


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 27 52 37 19 37 7 9 62 28 28 11 7
Low 16 5 4 4 1 2 12 7 13 1
Below cutoff


RefSeq Acc Id: ENSRNOT00000049357   ⟹   ENSRNOP00000040411
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,563,990 - 54,590,415 (+)Ensembl
Rnor_6.0 Ensembl1856,431,891 - 56,458,300 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000079360   ⟹   ENSRNOP00000075739
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,567,144 - 54,590,415 (+)Ensembl
Rnor_6.0 Ensembl1856,431,820 - 56,457,869 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000088988   ⟹   ENSRNOP00000072826
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,567,144 - 54,579,090 (+)Ensembl
Rnor_6.0 Ensembl1856,414,488 - 56,446,303 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000094400   ⟹   ENSRNOP00000079769
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,565,650 - 54,590,334 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000112990   ⟹   ENSRNOP00000086224
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,567,144 - 54,578,549 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000116788   ⟹   ENSRNOP00000090893
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,565,437 - 54,590,415 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000117928   ⟹   ENSRNOP00000085048
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1854,546,659 - 54,590,415 (+)Ensembl
RefSeq Acc Id: NM_001029901   ⟹   NP_001025072
Rat AssemblyChrPosition (strand)Source
GRCr81856,834,379 - 56,860,804 (+)NCBI
mRatBN7.21854,563,990 - 54,590,415 (+)NCBI
Rnor_6.01856,431,891 - 56,458,300 (+)NCBI
Rnor_5.01855,662,670 - 55,689,297 (+)NCBI
RGSC_v3.41857,080,324 - 57,107,295 (+)RGD
Celera1852,716,221 - 52,742,736 (+)RGD
RefSeq Acc Id: XM_006254813   ⟹   XP_006254875
Rat AssemblyChrPosition (strand)Source
GRCr81856,834,152 - 56,860,803 (+)NCBI
mRatBN7.21854,563,765 - 54,590,418 (+)NCBI
Rnor_6.01856,431,661 - 56,458,299 (+)NCBI
Rnor_5.01855,662,670 - 55,689,297 (+)NCBI
RefSeq Acc Id: XM_039096836   ⟹   XP_038952764
Rat AssemblyChrPosition (strand)Source
GRCr81856,834,155 - 56,860,803 (+)NCBI
mRatBN7.21854,563,814 - 54,590,418 (+)NCBI
RefSeq Acc Id: NP_001025072   ⟸   NM_001029901
- Peptide Label: precursor
- UniProtKB: A0A8I6AEN2 (UniProtKB/TrEMBL),   D4ACA7 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006254875   ⟸   XM_006254813
- Peptide Label: isoform X1
- UniProtKB: A0A0G2KBC4 (UniProtKB/TrEMBL),   A0A8I5ZZ98 (UniProtKB/TrEMBL),   A6IXF7 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000075739   ⟸   ENSRNOT00000079360
RefSeq Acc Id: ENSRNOP00000072826   ⟸   ENSRNOT00000088988
RefSeq Acc Id: ENSRNOP00000040411   ⟸   ENSRNOT00000049357
RefSeq Acc Id: XP_038952764   ⟸   XM_039096836
- Peptide Label: isoform X2
- UniProtKB: A0A0G2KBC4 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000086224   ⟸   ENSRNOT00000112990
RefSeq Acc Id: ENSRNOP00000085048   ⟸   ENSRNOT00000117928
RefSeq Acc Id: ENSRNOP00000079769   ⟸   ENSRNOT00000094400
RefSeq Acc Id: ENSRNOP00000090893   ⟸   ENSRNOT00000116788
Protein Domains
Ig-like   Ig-like C2-type   Protein kinase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q00495-F1-model_v2 AlphaFold Q00495 1-978 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13700816
Promoter ID:EPDNEW_R11337
Type:initiation region
Description:colony stimulating factor 1 receptor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01856,431,809 - 56,431,869EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2425 AgrOrtholog
BioCyc Gene G2FUF-7347 BioCyc
Ensembl Genes ENSRNOG00000018414 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000049357 ENTREZGENE
  ENSRNOT00000049357.5 UniProtKB/TrEMBL
  ENSRNOT00000079360.2 UniProtKB/TrEMBL
  ENSRNOT00000088988.2 UniProtKB/TrEMBL
  ENSRNOT00000094400.1 UniProtKB/TrEMBL
  ENSRNOT00000112990.1 UniProtKB/TrEMBL
  ENSRNOT00000116788.1 UniProtKB/TrEMBL
  ENSRNOT00000117928.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transferase(Phosphotransferase) domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro CSF-1_receptor UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_fold UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Immunoglobulin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_rcpt_3_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:307403 UniProtKB/TrEMBL
Pfam PF00047 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Csf1r PhenoGen
PIRSF CSF-1_receptor UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrPK_CSF1-R UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000018414 RatGTEx
SMART IGc2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SM00409 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF48726 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A0G2K3Y5_RAT UniProtKB/TrEMBL
  CSF1R_RAT UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Csf1r  Colony stimulating factor 1 receptor      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_regulation transcriptionally active only in undifferentiated myoblasts 727559